References

2011 Annual Data Report

2012 · External reference

Predictors of mortality in adults with cystic fibrosis

10.1002/ppul.20619 · 2007 · External reference

Is the type of chronic pulmonary infection a determinant of lung function outcomes in adult patients with cystic fibrosis?

2012 · External reference

10.1513/annalsats.201209-082oc · 2013 · Admitted local publication

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial

10.1016/j.jcf.2012.07.006 · 2012 · External reference

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis

10.1056/nejm199901073400104 · 1999 · External reference

Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis

10.1002/ppul.22693 · 2013 · External reference

Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin

10.1089/jamp.2011.0942 · 2013 · External reference

Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa

10.2165/00148581-200709001-00003 · 2007 · External reference

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

10.1001/jama.290.13.1749 · 2003 · External reference

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

10.1016/s0140-6736(02)11081-6 · 2002 · External reference

Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa

10.1378/chest.12-0628 · 2012 · External reference

Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome

10.1164/rccm.200601-071oc · 2006 · External reference

Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia

10.1371/journal.pone.0005806 · 2009 · External reference

Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells

10.1016/j.bbrc.2006.09.132 · 2006 · External reference

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health

10.1164/rccm.201207-1160oe · 2013 · External reference

Effects of azithromycin in Pseudomonas aeruginosa burn wound infection

10.1016/j.jss.2013.02.003 · 2013 · External reference

Azithromycin appears to inhibit inhaled tobramycin but not aztreonam when targeting P. aeruginosa in the CF airway [abstract]

2013 · External reference

Quantification of biofilm structures by the novel computer program COMSTAT

10.1099/00221287-146-10-2395 · 2000 · External reference

Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?

10.1093/jac/dkq342 · 2010 · External reference

Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips

10.1128/jcm.43.9.4480-4485.2005 · 2005 · External reference

Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses

10.1128/aac.40.11.2582 · 1996 · External reference

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial

10.1016/j.jcf.2010.10.003 · 2011 · External reference

2005 Annual Data Report

2006 · External reference

Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis

10.1378/chest.123.5.1495 · 2003 · External reference

Microbiological and immunologic considerations with aerosolized drug delivery

10.1378/chest.120.3_suppl.118s · 2001 · External reference

Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model

10.1128/aac.00372-10 · 2010 · External reference

Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis

10.1007/s10096-009-0774-9 · 2009 · External reference

Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane

10.1128/aac.49.4.1377-1380.2005 · 2005 · External reference

Interactions of macrolide antibiotics (Erythromycin A, roxithromycin, erythromycylamine [Dirithromycin], and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models

10.1006/taap.1999.8632 · 1999 · External reference

Effect of calcium and magnesium ions on the susceptibility of Pseudomonas species to tetracycline, gentamicin polymyxin B, and carbenicillin

10.1128/aac.7.5.596 · 1975 · External reference

The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing

10.1093/infdis/162.2.408 · 1990 · External reference

Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa

10.1128/aac.01071-07 · 2008 · External reference

Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria

10.1128/aac.37.2.354 · 1993 · External reference

Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms

10.1128/aac.49.9.3858-3867.2005 · 2005 · External reference

In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection

10.1128/aac.33.3.277 · 1989 · External reference

Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses

10.1136/bmj.c117 · 2010 · External reference

Interaction revisited: the difference between two estimates

10.1136/bmj.326.7382.219 · 2003 · External reference

Interaction 3: how to examine heterogeneity

10.1136/bmj.313.7061.862 · 1996 · External reference

Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis

10.1164/rccm.200502-218oc · 2005 · External reference